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Abstract Polymerase chain reaction was used to determine 
whether opioid receptor-like sequences are present in species 
from the protostome and deuterostome branches of the metazoan 
kingdom. Multiple opioid receptor-like sequences were found in 
all vertebrates, but no specific fragments were obtained from any 
invertebrates. Delta, mu, kappa and ORL-1 receptors were 
identified from bovine DNA, and three different opioid receptor- 
like fragments were identified from the other vertebrates 
analyzed. The data suggest hat the opioid receptor gene family 
has been highly conserved uring vertebrate volution and that, 
even in the primitive jawless fish, multiple members of the opioid 
receptor family appear to be present. 
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1. Introduction 
Opioid drugs have many different physiological effects and 
the actions of these drugs are mediated through membrane- 
associated opioid receptors. Four members of the opioid re- 
ceptor family have been cloned: delta (DOR) [1,2]; mu 
(MOR) [3 5]; kappa (KOR) [6,7]; and opioid receptor like 
(ORL-1) [8,9]. The opioid receptors are typical G-protein 
coupled receptors containing seven transmembrane (TM) do- 
mains. In mammalian species, all members of the receptor 
family have homologous protein sequences and conserved in- 
tron/exon boundaries [10]. Thus, it is anticipated that the 
opioid receptor family arose from a common ancestral gene 
via gene duplication. The endogenous ligands for these recep- 
tors are derived from four precursors: pro-orphanin FQ, pro- 
enkephalin, pro-dynorphin and pro-opiomelanocortin. Pro- 
orphanin FQ is processed into peptides elective for ORL-I 
receptors, and the other three generate delta-, mu-, and kap- 
pa-selective peptides. In the frog, two additional opioid pep- 
tide precursors -- pro-dermorphin a d pro-deltorphin --  have 
been detected, and their bioactive processing products (the 
dermorphins and deltorphins) include a D-amino acid adjacent 
to the N-terminal tyrosine residue [11,12]. Opioid peptides 
have been identified in a number of invertebrate species [13 
15]. Moreover, there are reports of opioid binding sites in 
protostomes [16,17], but they exhibit unusual ligand selectiv- 
ities and thus may not correspond to the cloned opioid recep- 
tor family. 
We designed a polymerase chain reaction (PCR) strategy to 
identify all members of the opioid receptor family and used it 
to attempt to trace the opioid receptors through a wide evolu- 
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tionary range of metazoan classes. The analysis of opioid 
receptors in lower species, in addition to providing phyloge- 
netic information, may give insights into structural elements 
necessary for receptor function through identification of resi- 
dues conserved in the receptor family during evolution. 
We describe here the partial sequences of the opioid recep- 
tor gene family identified from six vertebrates including the 
hagfish. However, this strategy failed to identify opioid recep- 
tor-like sequences in any invertebrates. 
2. Materials and methods 
2.1. Samples 
Genomic DNA was isolated as described [18] from the following 
species: bovine, Bos taurus; chicken, Gallus domesticus; bullfrog, 
Rana catesbeiana; striped bass, Morone saxatilis; thresher shark, Alo- 
pias vulpinus; Pacific hagfish, Eptatretus toutii; amphioxus, Bran- 
chiostoma floridae; tunicate, Polyandrocarpa maxima; acorn worm, 
Saccoglossus kowalevskii; sea urchin, Arbaeia punctulata; fruitfly, 
Drosophila melanogaster; shrimp, Alpheus heterochaelis; ribbed mus- 
sel, Modiolus modiolus; earthworm, Lumbricus terrestris; Caenorhab- 
ditis elegans and flat worm, Bdelloura candida. 
2.2. Oligonucleotide primers 
Degenerate oligonucleotides were designed to amplify a 162 bp 
fragment of all members of the opioid receptor family from human, 
rat and mouse. The primer sequences correspond to regions of amino 
acid identity in the boundary between the first intracellular loop and 
transmembrane domain 2 (TM2) and in transmembrane domain 3 
(TM3) of the cloned mammalian opioid receptor family. (These se- 
quences are underlined in Fig. 1.) Primers R1 and Ra encode the 
sequence Lys-Thr-Ala-Thr-Asn-Ile-Tyr, and primers R2 and Rb en- 
code the sequence Asp-Tyr-Tyr-Asn-Met-Phe-Thr. The Ra and Rb 
primers are more degenerate v rsions of R1 and R2. The sequences 
were: 
R1 : 5'-GAAGAC(CGT)GC(CA)ACCAACATCTA 
R2: 5'-GT(AG)AACAT(AG)TT(AG)TAGTA(AG)TC 
Ra: 5'- GAA(AG)AC(GATC)GC(GATC)AC(GATC)AA(TC)AT- 
(TCA)TA 
Rb: 5'-GT(AG)AACAT(AG)TT(AG)TA(AG)TA(AG)TC 
2.3. DNA amplification 
Genomic DNA (0.1 1 ].tg) was used with the above primers in a 
DNA Pacer thermocycler (BeUco Biotechnology) using Taq-polymer- 
ase. PCR reactions were carried out in 50 gl volumes containing 50 
mM KCI, 20 mM Tris-HC1, pH 8.4, 2 mM MgCI2, 50-200 pmol of 
each primer, and 2.5 U of Taq polymerase. An initial 3-min denatura- 
tion step at 94°C was followed by 30 cycle amplification. Cycling 
parameters were 94°C for 1 min, 55-57°C for 1 rain, and 72°C for 
40 s. 
2.4. Cloning and sequencing of amplified fragments 
After amplification, the resulting PCR products were gel-purified, 
blunt-ended with Pfu DNA polymerase, then cloned into pCR-Script 
Sk(+) (Stratagene Inc., La Jolla, CA). Alternatively, PCR products 
were cloned into pCRII vector with the TA Cloning Kit (Invitrogen, 
San Diego, CA). After transformation, clones containing inserts were 
selected using IPTG and X-Gal. Multiple independent clones for each 
species were sequenced in both directions using Sequenase (United 
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States Biochemical, Cleveland, OH). Alignments and phylogenetic 
analyses were performed using MacVector (Oxford Molecular Group, 
Campbell, CA) and MegAlign (DNASTAR, Madison, WI). 
3. Results and discussion 
Using the PCR strategy, we were able to amplify sequences 
from human, bovine, rat, mouse, chicken, frog, and bass 
genomic DNA using the RI and R2 primers. The sequences 
of human, rat and mouse receptors have been reported by 
other groups [1,4,8,19-21] and were not analyzed in this 
study. The more degenerate Ra and Rb primers were able 
to amplify sequences from shark and hagfish. After se- 
quencing many clones generated by PCR of bovine DNA, 
four different sequences were identified which corresponded 
to all four receptor types (Fig. 1). Of the 56 bovine clones 
sequenced, 50 were KOR, three were ORL-1, two were DOR, 
and only one was MOR. Similarly, of 64 chicken clones ana- 
lyzed, 59 corresponded to MOR, one to DOR, and three had 
high homology to ORL-I. This apparent primer bias shows 
that the technique does not seem to amplify and clone indi- 
vidual receptors with equal efficacy. 
Three different opioid receptor-like sequences were detected 
in chicken, bass and frog with the R1 and R2 primers and 
three each in shark and hagfish using Ra and Rb primers (Fig. 
1). Sequences homologous to both the delta and mu opioid 
receptors were identified in all four species, and the third 
sequence identified was most homologous to either the kappa 
receptor or ORL-1. This failure of the primers to obtain four 
receptor types from each species may be due to the above 
mentioned primer bias. Alternatively, it is possible that only 
three members of the opioid receptor family are present in the 
genome of these species. The identification of four bovine 
sequences confirms that the strategy can detect all members 
of the opioid receptor family, at least in mammals, with the 
caveat that every member is not equally represented in the 
cloned products. 
Because multiple clones were sequenced, occasional Taq 
polymerase rrors were found at approximately the expected 
rate (0.25%). For clones which had only a single isolate, the 
certainty of the sequence is, of course, subject to this same 
error rate. 
3.1. Opioid receptor sequences in mammals 
Among the mouse, rat, human, and bovine sequences ob- 
tained over the region we analyzed, there was between 83% 
and 91% identity at the nucleic acid level among the four 
receptor types, but the predicted amino acid sequences were 
96-100% conserved. The identifcation of only four bovine 
receptors uggests that there are no other members of the 
opioid receptor family in the mammalian genome, and that 
the reported sub-types of opioid receptors are generated either 
by alternative splicing, post-translational modification or by 
non-homologous G-protein coupled receptors [22]. 
3.2. Opioid receptor-like sequences in chicken, frog, bass, and 
shark 
Unambiguous DOR and MOR clones were isolated from 
chicken, frog, bass, and shark. However, no kappa-like se- 
quences were found in the chicken or shark, although ORL- 
l-like fragments were present. There are reports that there are 
kappa receptors in chicken brain. The kappa selective ligand 
U-50,488 can induce a concentration-dependent hyperpolari- 
zation and inhibit ion conductance in chick ganglia [23]. This 
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Bov ine  DOR (2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  V . . . .  
Rat  DOR (p) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Mouse  DOR (p) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Ch ick  DOR (i) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  L . . . .  
F rog  DOR (4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  V , . . V . . . .  
Bass  DOR (6) . . . . .  F . . . . . . . . . . . . . . . . . .  S . . . . . .  P . . . V . I A . 
Shark  DOR (2) . . . . . . . . . . . . . . . . . . . . . . . .  D . . . . . . . . . .  T . . . .  
Human MOR (p) . . . . . . . . . . . . . . . . . . . . . . . . . .  V N 
Bov ine  MOR (i) . . . . . . . . . . . . . . . . . . .  V N 
Rat  MOR (p) . . . . . . . . . . . . . . . . . . . . . . . . . .  V N 
Mouse  MOR (p) . . . . . . . . . . . . . . . . . . . . . . . . . .  V N 
Ch ick  MOR (59)  . . . . . . . . . . . . . . . . . . .  V N 
F rog  MOR (8) . . . . . . . . . . . . . . . . . . .  V N 
Bass  MOR (8) . . . . . . . . . .  V . . . . . . . .  V N 
Shark  MOR (4) . . . . . . . . . . . . . . . . . . .  V N 
Human KOR (p) . . . . . . . . . . . . . . . . .  V T . M . . . .  T V 
Bov ine  KOR (50)  . . . . . . . . . .  V T . M . . . .  T V 
Rat  KOR (p) . . . . . . . . . . . . . . . . .  V T . M . . . . .  V 
Mouse  KOR (p) . . . . . . . . . . . . . . . . .  V T . M . . . . .  V 
F rog  KOR (6) . . . . . . . . . .  V T . M . . . .  T E 
Bass  KOR (i) . . . . . . . . . .  V T . M . . . .  T D 
Human ORL I  (p) . . . . . . . . . . . . . . .  T . V L L . . . . .  G T D 
G . . . . .  T I .  I I . . . . . . . . .  
G . . . . .  T I .  I I . .  
G . . . . .  T I .  I I . . . . . . . . .  
G . . . . .  N I .  I I . . . . . . . . .  
G . . . . .  T I .  I I . .  
G . . . . .  N I V  I I . .  
G . . . . .  DA,  M M . .  
G . . . . .  K . . . .  V I M . .  
.NS  . . . .  DV,  I . I  . . . . . . . . .  
.NS  . . . .  DV.  V . I . .  
.NS  . . . .  DV.  I . I  . . . . . . . . .  
.NS  . . . .  DV.  I . I  . . . . . . . . .  
.SS  . . . .  D I .  I . M . .  
LN  . . . . . .  VV  V F I . .  
. L G F  . . . .  NA  T . I A  . . . . . . . .  
Bov ine  ORL I  (3) . . . . . . . .  T . VL  L . . . . .  R T D V  . L G F  . . . .  NA  T . I A . 
Rat  ORL I  (p) . . . . . . . . . . . . . . .  T . VL  L . . . . .  R T D I  . L G F  . . . .  NA  T . IA  . . . . . . . .  
Mouse  ORL I  (p) . . . . . . . . . . . . . . .  T . V L L . . . . .  G T D I . L G F . . . .  N A T . I A . . . . . . . .  
Ch ick  ORL I  (3) . . . . . . . .  T . C L M . . . . .  GT  DT  F L G F  . . . .  NV  IA  I . 
Shaxk  ORL I  (I) . . . . . . . . . .  E L I . . . . .  A T D T . L G F . . . .  N I I A I . 
Hagf i sh  A (7) . L . . . . . . . . . . . . . . . .  G . V T M I G S . . . .  L G . . . I I . G 
Hagf i sh  B (2) . . . . . . . . . . . .  I . . . . . . .  N , . L G S . . . .  G . . . .  V . V .  
Hagf i sh  C (i) . . . . . . . . . .  V . . . . . . . .  V N . . L D . . . . .  Q F . . . V A M . 
Fig. I. Alignment of all deduced amino acid sequences of PCR fragments identified from vertebrates with the published human and rodent se- 
quences. The value in parentheses after the name is the number of clones sequenced, or (p) for published ata. Underlined are the sequences 
corresponding to the primers, and shaded are TM2 and part of TM3. The area in between (residues 2343) corresponds to the first extracellular 
loop. Only changes from the human DOR sequence are shown. 
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Fig. 2. Phylogenetic analysis of nucleotide sequences between primers of all opioid receptor-like sequences identified in vertebrates. Alignment 
was performed using MegAlign (DNASTAR). The human somatostatin receptor (Human SSTR) is shown for comparison and X axis shows 
number of substitution events. 
drug can also impair memory formation in chicks, and the 
kappa selective antagonist nor-binaltorphimine enhances 
memory formation in a peck avoidance paradigm [24]. 
Furthermore, autoradiographic [25] and immunohistochemi- 
cal [26] studies indicate the presence of kappa receptors in 
the chicken brain. This evidence for the existence of the kappa 
receptor in the chicken suggests that our PCR strategy simply 
failed to detect kappa receptors in this species. Nothing is 
known about opioid receptors in shark, although beta-endor- 
phin-like peptides have been identified in one species - -  the 
spiny dogfish [27]. 
In contrast o the chicken and shark, KOR was found in 
frog and bass DNA, but ORL-l-l ike fragments were not. A 
plethora of evidence xists for the presence of opioid receptors 
in amphibians, and kappa-like binding sites appear to be the 
predominant opioid receptor in frog brain [28,29]. Addition- 
ally, genes encoding frog pro-opiomelanocortin and pro-enke- 
phalin have been cloned, and pro-dynorphin derived peptides 
[30] have been identified in frogs. The deltorphans and der- 
morphins were identified in frog skin, and appear to be rela- 
tively selective for the delta and mu receptors, respectively. 
3.3. Opioid receptor-like sequences in hagfish 
The hagfish is a jawless fish which occupies a key position 
in metazoan evolution. This exceptionally slimy fish is one of 
the only surviving members of the most primitive vertebrate 
class, agnathans, which diverged from the main line of verte- 
brate evolution approximately 470 million years ago [31]. 
Three different opioid receptor-like sequences were identified 
from the hagfish genome (Fig. 1). These sequences are clearly 
members of the opioid receptor family with between 69% and 
85% amino acid identity with individual members of the hu- 
man opioid receptor family (Table 1). Amino acid identity 
among the three hagfish sequences i between 70% and 83°/,, 
(Table 1), similar to the identity among the human opioid 
receptor family. 
All three hagfish sequences are most homologous to MOR 
and DOR at both the amino acid and nucleotide level (Table 
l), and we have named these gene fragments hagfish A, B and 
C, because of the difficulty in classifying them. In an earlier 
study, we reported the extended, but still incomplete sequence 
of hagfish A [18], but even with additional 3' sequence it 
remained difficult to classify. It is interesting that the first 
extracellular loops of hagfish A, B and C are devoid of 
charged amino acids except for the conserved Lys residue at 
position 42 and an Asp residue in hagfish C at position 32. All 
the other vertebrate sequences except he mammalian mu re- 
ceptors have multiple charges in this loop. Clearly, obtaining 
full-length clones from this species would provide valuable 
tools for structure-function studies of opioid receptors and 
might shed more light on the origin of the opioid receptor 
family. Because these structures are significantly different 
from their mammalian counterparts, it might be anticipated 
that the pharmacological profiles are different. 
3.4. Lack of opioid receptor-like sequences in invertebrates 
Using this strategy, no opioid receptor-like sequences were 
obtained from protostomes, including C. elegans and Droso- 
phila, or from any invertebrate species tested - -  not even from 
amphioxus, a transition species between invertebrates and ver- 
Table 1 
Comparison of sequence identity of opioid receptor-like sequences 
from hagfish with human sequences in the region spanning intracel- 
lular loop 1 to TM3 
Nucleotide Amino acid 
Human Hagfish Human Hagfish 
~ ~ o A B C ~ ~ ~ o A B C 
Hagfish A 
Hagfish B 
Hagfish C 
60 56 48 49 -58  50 76 76 72 69 -76  70 
72 72 55 55 65 85 85 80 74 - -  83 
70 65 57 58 82 85 78 72 
Values shown are percent identity and were calculated using MegAl- 
ign (DNASTAR). Nucleotide comparisons were made in the sequence 
between primers. 8(DOR), ~(MOR), ~c(KOR), o(ORL-I). 
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tebrates. It is possible that the degenerate primers may not 
recognize the genes from species which have a large evolu- 
tionary gap from mammals. Alternatively, lower species may 
not have opioid receptors homologous to the vertebrates - -  an 
independent system of opioid receptors may have evolved in 
the protostomes. 
3.5. Delta and mu opioid receptor-like sequences 
In this study, delta and mu opioid receptor-like sequences 
were found in all representative species of vertebrates that 
were analyzed, and each receptor type is highly conserved 
during vertebrate volution (Fig. 1). Chicken and frog DOR 
and MOR showed exceptionally high homology with their 
mammalian counterparts (between 96 and 98% amino acid 
identity), and retained the same charge profile. The bass and 
shark sequences are slightly more divergent, with most amino 
acid substitutions in the extracellular loop and the C-terminal 
half of TM2. Although the amino acid sequences between 
some species are identical, the nucleotide sequences are 
more divergent as would be anticipated (see Fig. 2). 
Bass DOR was noteworthy in a number of respects, having 
changes at position 13 (Leu to Phe), 32 (Glu to Ser), and 39 
(Leu to Pro). Leucine at position 13 in TM2 is present in all 
opioid receptors that have been analyzed except the bass 
DOR. The Glu to Ser changes the charge profile in this 
loop and the Leu to Pro changes the predicted secondary 
structure in this region. Also of interest is that mammalian, 
frog and chicken MOR have a neutral Thr residue at position 
38 in the first extracellular loop, whereas hark MOR contains 
a positively charged Lys at this position and bass MOR has a 
negatively charged Asp residue. These changes may affect lig- 
and selectivity. 
3.6. Kappa opioid receptor-like sequences 
Kappa opioid receptor-like sequences were identified in bo- 
vine, frog and bass (Fig. 1). Frog KOR has 91% identity to 
the human kappa receptor and substantially less identity to 
the other opioid receptors ( < 82%). Both frog and bass KOR 
gain a negatively charged residue at position 28, which is a 
valine residue in all the mammalian kappa receptors. It is 
interesting that this negatively charged residue is also found 
in ORL-1, and it is tempting to speculate that orphanin FQ 
(nociceptin) may bind to these receptors, since no ORL-1 was 
identified in these species. 
3. 7. ORL-1 opioid receptor-like sequences 
We identified ORL-1 sequences in bovine, chicken, and in 
the primitive cartilaginous fish, the thresher shark (Fig. 1). All 
are highly conserved, except at positions 18 and 26. At posi- 
tion 18 in TM2, chicken has a Cys and shark a Glu where as 
in all other receptors this is a Val or Ala residue. The shark is 
thus highly unusual in that TM2 has two negatively charged 
residues. 
3.8. Conclusions 
As shown in Fig. 1, over the 54 amino acid region from the 
first intracellular loop to TM3 there is high homology among 
the human mu, delta, kappa and ORL-1 receptors (between 
70 and 87% amino acid identity). Within this region there are 
two aspartate residues in TM2 and TM3. Site-directed muta- 
genesis and deletion studies on the rat mu opioid receptor 
showed that both of these aspartate residues are important 
for binding to mu selective ligands [32], but the Asp in TM3 
is not as important for DOR binding [33]. Our data suggests 
these two transmembrane aspartate residues are conserved in 
all opioid receptor members in all vertebrate species analyzed. 
It can be assumed that these and other conserved residues are 
potentially significant elements for maintaining the functions 
of the opioid receptor gene family under the pressure of evo- 
lution. 
Opioid receptor-like sequences were identified in all classes 
of vertebrates, including bovine, chicken, frog, bass, shark 
and hagfish and demonstrate hat the degenerate primers de- 
signed from the mammalian opioid receptors can be used to 
identify opioid receptor-like sequences in lower vertebrate spe- 
cies. Comparison of the DNA and amino acid sequences sug- 
gest that the opioid receptor gene family is evolutionarily old, 
because the partial sequences are well preserved throughout 
vertebrate evolution (Figs. 1 and 2). Among the members of 
the opioid receptor family, the delta and mu opioid receptors 
appear to be the most conserved in the vertebrates that were 
analyzed. Three opioid receptor-like sequences were found in 
hagfish, and although their unequivocal classification was dif- 
ficult, their presence clearly indicates that even at this early 
stage in evolution, multiple opioid receptors are present. 
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